Shenzhen Chipscreen Biosciences Co., Ltd.

Shanghai Stock Exchange 688321.SS

Shenzhen Chipscreen Biosciences Co., Ltd. Free Cash Flow for the year ending December 31, 2023: USD -54.41 M

Shenzhen Chipscreen Biosciences Co., Ltd. Free Cash Flow is USD -54.41 M for the year ending December 31, 2023, a -5.21% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Shenzhen Chipscreen Biosciences Co., Ltd. Free Cash Flow for the year ending December 31, 2022 was USD -51.71 M, a -100.75% change year over year.
Shenzhen Chipscreen Biosciences Co., Ltd. Free Cash Flow for the year ending December 31, 2021 was USD -25.76 M, a 30.70% change year over year.
Shenzhen Chipscreen Biosciences Co., Ltd. Free Cash Flow for the year ending December 31, 2020 was USD -37.17 M, a -64.28% change year over year.
Shenzhen Chipscreen Biosciences Co., Ltd. Free Cash Flow for the year ending December 31, 2019 was USD -22.63 M, a -31.93% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

Shanghai Stock Exchange: 688321.SS

Shenzhen Chipscreen Biosciences Co., Ltd.

CEO	Dr. Xian-Ping Lu
IPO Date	Aug. 12, 2019
Location	China
Headquarters	Biology Incubator Building 2
Employees	1,057
Sector	Health Care
Industries Pharmaceuticals Biotechnology Chemicals & Advanced Materials

Description

Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of original small molecule drugs. The company develops precursor compounds and original new drug product lines that are in various research phase of the specific global intellectual property protection in three areas, such as cancer, metabolic diseases, and autoimmune diseases. Shenzhen Chipscreen Biosciences Co., Ltd. was founded in 2001 and is based in Shenzhen, China.

Key trends

Past 5 years